Guo WF - Search Results

1

A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients.

Liu Y, Liu B, Li XY, Li JJ, Qin HF, Tang CH, Guo WF, Hu HX, Li S, Chen CJ, Liu B, Gao HJ, Liu XQ. Liu Y, et al. Among authors: guo wf. J Exp Clin Cancer Res. 2011 Dec 6;30(1):111. doi: 10.1186/1756-9966-30-111. J Exp Clin Cancer Res. 2011. PMID: 22142557 Free PMC article.

2

Interleukin-4 -590T/C polymorphism influences the susceptibility to nonsmall cell lung cancer.

Li X, Shi W, Yu G, Lin L, Yang B, Li J, Guo W, Tang C, Wang H, Gao H, Qin H, Liu Y, Liu X. Li X, et al. DNA Cell Biol. 2012 May;31(5):797-800. doi: 10.1089/dna.2011.1425. Epub 2011 Dec 5. DNA Cell Biol. 2012. PMID: 22142023

3

[Clinical investigation of efficacy of third-line and beyond pemetrexed treatment in advanced non-squamous non-small cell lung cancer].

Yu F, Liu X, Li X, Li J, Guo W, Qin H, Gao H. Yu F, et al. Zhongguo Fei Ai Za Zhi. 2012 Feb;15(2):117-21. doi: 10.3779/j.issn.1009-3419.2012.02.10. Zhongguo Fei Ai Za Zhi. 2012. PMID: 22336241 Free PMC article. Chinese.

4

[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].

Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X. Li J, et al. Zhongguo Fei Ai Za Zhi. 2012 May;15(5):299-304. doi: 10.3779/j.issn.1009-3419.2012.05.09. Zhongguo Fei Ai Za Zhi. 2012. PMID: 22613337 Free PMC article. Clinical Trial. Chinese.

5

[Clinic characteristics and prognosis in 102 non-small cell lung cancer patients less than 40 years old].

Qu L, Qin H, Liu X, Gao H, Li J, Wang W, Tang C, Guo W, Li X. Qu L, et al. Zhongguo Fei Ai Za Zhi. 2013 Feb;16(2):73-7. doi: 10.3779/j.issn.1009-3419.2013.02.03. Zhongguo Fei Ai Za Zhi. 2013. PMID: 23425898 Free PMC article. Chinese.

6

[A case report of patient with advanced non-small cell lung cancer by five times EGFR-TKIs therapy].

Guo W, Gao H, Liu X. Guo W, et al. Zhongguo Fei Ai Za Zhi. 2013 Jun;16(6):330-2. doi: 10.3779/j.issn.1009-3419.2013.06.11. Zhongguo Fei Ai Za Zhi. 2013. PMID: 23769350 Free PMC article. Chinese. No abstract available.

7

[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].

Tang C, Li X, Guo W, Li J, Qin H, Wang W, Qu L, An J, Gao H, Liu X. Tang C, et al. Zhongguo Fei Ai Za Zhi. 2013 Jul;16(7):345-52. doi: 10.3779/j.issn.1009-3419.2013.07.03. Zhongguo Fei Ai Za Zhi. 2013. PMID: 23866664 Free PMC article. Chinese.

8

[Comparison of Efficacy and Safety of Different Therapeutic Regimens as  Second-line Treatment for Small Cell Lung Cancer].

Li Z, Liu X, Li J, Gao H, Tang C, Li X, Guo W, Qin H, Wang W, Qu L, Chen J. Li Z, et al. Zhongguo Fei Ai Za Zhi. 2015 May;18(5):280-8. doi: 10.3779/j.issn.1009-3419.2015.05.05. Zhongguo Fei Ai Za Zhi. 2015. PMID: 25975298 Free PMC article. Chinese.

9

[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].

Tang CH, Liu XQ, Gao HJ, Li JJ, Guo WF, Li XY, Wang WX, Liu B, Qu LL, Wang WW. Tang CH, et al. Among authors: guo wf. Zhonghua Zhong Liu Za Zhi. 2010 Feb;32(2):143-7. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 20403247 Clinical Trial. Chinese.

10

[A Case Report of Erlotinib as First-line Therapy in Extensive Metastatic Patient with Advanced Non-small Cell Lung Cancer.].

Guo W, Liu X. Guo W, et al. Zhongguo Fei Ai Za Zhi. 2009 Dec 20;12(12):1374-6. doi: 10.3779/j.issn.1009-3419.2009.12.31. Zhongguo Fei Ai Za Zhi. 2009. PMID: 20723403 Free article. Chinese. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters